All In Biotech

Drug Trial Radar · NCT07892625

A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With Extensive Stage Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

338

Planned (sponsor's estimate)

Start

Nov 15, 2026

Primary completion

Sep 15, 2028

Study completion Sep 15, 2029

Sponsor

Lead sponsor
Hansoh BioMedical R&D CompanyIndustry
Sponsor type
Industry
First posted
Oct 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label Phase I study evaluating the safety, tolerability, pharmacokinetic, and efficacy of Intravenous HS-20093 in combination with ZG006 with or without adebrelimab in patients with extensive-stage small cell lung cancer.

Conditions

  • Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Interventions

  • HS-20093 for InjectionDrug

    The patient will be treated with HS-20093.

  • ZG006Drug

    The patient will be treated with ZG006.

  • Adebrelimab InjectionDrug

    The patient will be treated with adebrelimab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The maximum tolerated dose (MTD) or maximum applicable dose (MAD) for combination treatmentsTime frame: Up to day 21 or 28 from the first dose
  2. The incidence rate of dose-limiting toxicities (DLT) events in combination treatmentsTime frame: Up to day 21 or 28 from the first dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.